Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Juluca

Gilead Sciences

Gilead and Achillion see 100% success rate in hep C trial

New combination treatment aims to compete in a rapidly evolving market for the disease

- PMLiVE

GSK hints at more restructuring following income drop

Company experiences a tough 2014 with Advair competition and China bribery scandal

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

Gilead Sciences

Gilead cuts hepatitis C drug prices in Germany

Discount on Sovaldi and Harvoni follows similar agreement in France

- PMLiVE

Germany gives green light to Viiv’s Triumeq for HIV

But IQWiG recommendation only covers previously untreated adults

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

- PMLiVE

AIDS pandemic now at ‘the beginning of the end’

ONE Campaign says drug access is making the difference, but there's still more to do

- PMLiVE

France agrees lowest Sovaldi pricing in EU

Government brings cost of hepatitis C drug to €5,000 below list price

- PMLiVE

Triple therapy ‘might cure hep C in six weeks’

Phase II trials shows promise for Merck and Gilead drugs

- PMLiVE

GSK to sell off part of its HIV venture ViiV Healthcare

And sets out new restructure programme as US Seretide sales hit

- PMLiVE

Russian HIV vaccine heading for phase II trials

But trials could be affected by lack of funding

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links